Fox Chase Cancer Center

An analysis of prostate cancer trends in California revealed an unexpected spike in distant-stage disease cases between 2011 and 2021.

The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.

More men with limited life expectancy and certain localized prostate cancers have received definitive treatment over the past 2 decades despite shifts toward active surveillance, according to results of a retrospective study.

Medical Group Management Association has awarded Disha Sawhney, FACHDM, FRSPH, with the 2024 Future Five Award.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights current challenges within the EGFR-mutated lung cancer space.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.

J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, spoke with Healio about monitoring patients with recurrent EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights important takeaways for interventional pulmonologists and other providers who may see patients with EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights potential treatments options coming to the EGFR-mutated lung cancer space.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.